Cell Engineering and Molecular Pharming for Biopharmaceuticals

Abdullah, Mokhtar; Rahmah, Anisa ur; Sinskey, Anthony J.; Rha, ChoKyun

doi:10.2174/1874104500802010049

Cited by 15 publications

(6 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of these are complex glycoproteins produced from genetically engineered mammalian cells in culture (Abdullah et al, 2008). The control of post-translational modification in these culture systems is a challenge but is needed to ensure product consistency and quality (Durocher and Butler, 2009;Wurm, 2004).…”

Section: Introductionmentioning

confidence: 99%

High productivity of human recombinant beta-interferon from a low-temperature perfusion culture

Rodrı́guez

Spearman

Tharmalingam

et al. 2010

Journal of Biotechnology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

High productivity of human recombinant beta-interferon from a low-temperature perfusion culture

Rodrı́guez

Spearman

Tharmalingam

et al. 2010

Journal of Biotechnology

View full text Add to dashboard Cite

“…To this end, industrial biotechnology flourished. Significant work has been done to generate a broad number of natural products, their analogs, as well as different classes of useful intermediates such as isoprenoids, flavonoids, stilbenes, polysaccharides and glycoproteins, and alcohols (Abdullah et al, 2008 ). These substances have potential applications as pharmaceuticals, fine chemicals and biofuels (Otero and Nielsen, 2010 ; van Summeren-Wesenhagen and Marienhagen, 2013 ).…”

Section: Flavonoid Combinatorial Biosynthesis Of Agricultural/pharmacmentioning

confidence: 99%

When plants produce not enough or at all: metabolic engineering of flavonoids in microbial hosts

et al. 2015

View full text Add to dashboard Cite

As a result of the discovery that flavonoids are directly or indirectly connected to health, flavonoid metabolism and its fascinating molecules that are natural products in plants, have attracted the attention of both the industry and researchers involved in plant science, nutrition, bio/chemistry, chemical bioengineering, pharmacy, medicine, etc. Subsequently, in the past few years, flavonoids became a top story in the pharmaceutical industry, which is continually seeking novel ways to produce safe and efficient drugs. Microbial cell cultures can act as workhorse bio-factories by offering their metabolic machinery for the purpose of optimizing the conditions and increasing the productivity of a selective flavonoid. Furthermore, metabolic engineering methodology is used to reinforce what nature does best by correcting the inadequacies and dead-ends of a metabolic pathway. Combinatorial biosynthesis techniques led to the discovery of novel ways of producing natural and even unnatural plant flavonoids, while, in addition, metabolic engineering provided the industry with the opportunity to invest in synthetic biology in order to overcome the currently existing restricted diversification and productivity issues in synthetic chemistry protocols. In this review, is presented an update on the rationalized approaches to the production of natural or unnatural flavonoids through biotechnology, analyzing the significance of combinatorial biosynthesis of agricultural/pharmaceutical compounds produced in heterologous organisms. Also mentioned are strategies and achievements that have so far thrived in the area of synthetic biology, with an emphasis on metabolic engineering targeting the cellular optimization of microorganisms and plants that produce flavonoids, while stressing the advances in flux dynamic control and optimization. Finally, the involvement of the rapidly increasing numbers of assembled genomes that contribute to the gene- or pathway-mining in order to identify the gene(s) responsible for producing species-specific secondary metabolites is also considered herein.

show abstract

“…Many promoters, codon-optimized ORFs, 5'UTR, 3'UTR and peptides have been tested to enhance the transcription and translation levels and therefore the yield production of recombinant proteins (Buyel, Kaever, Buyel, & Fischer, 2013;Gallie, 2002;Kanoria & Burma, 2012;Laguia-Becher et al, 2010). Promoter studies are very useful for increasing the expression and accumulation of the heterologous pharmaceutical recombinant proteins, such as the strong and ubiquitous 35S CaMV promoter, or for targeting spatiotemporal expression features by using promoters specific to certain cells, tissues or organs (Abdullah, Rahmah, Sinskey, & Rha, 2008;Makhzoum, Petit-Paly, St Pierre, & Bernards, 2011).…”

Section: Re-engineering the Expression Cassettementioning

confidence: 99%

Untitled

2014

Plant Sci. Today

View full text Add to dashboard Cite

Plant molecular pharming is a promising concept based on the large-scale production of recombinant proteins encompassing antibodies, vaccines, enzymes and peptides for human or veterinary uses and treatments. This new branch of the biopharmaceutical industry offers practical and safety advantages over other traditional production systems. In higher plants, the complex cellular machinery makes possible synthesis and posttranslational modifications of heterologous protein macromolecules. The limiting obstacle to using this system at an industrial scale is most often the low yield of the recombinant proteins produced in host plants. To improve production levels, many studies have been focusing on the choice of plant species, tissues, organs and cell suspension cultures and/or various upstream and downstream constituents in the expression cassette. New engineering technologies in plant molecular pharming have emerged that rely on the usefulness of using soybean agglutinin (SBA), hydrophobin, zein and elastin-like peptide tags which are employed to extract and purify recombinant proteins in

show abstract

Cell Engineering and Molecular Pharming for Biopharmaceuticals

Cited by 15 publications

References 84 publications

High productivity of human recombinant beta-interferon from a low-temperature perfusion culture

High productivity of human recombinant beta-interferon from a low-temperature perfusion culture

When plants produce not enough or at all: metabolic engineering of flavonoids in microbial hosts

Untitled

Contact Info

Product

Resources

About